BRUSSELS, BELGIUM - Elanco, the animal health division of Eli Lilly and Company (NYSE:LLY), announced the closing of its acquisition of the animal health business of Janssen Pharmaceutica NV, a Johnson & Johnson Company. Elanco gained final approval from the European Commission today.
The acquisition continues Elanco’s growth in Europe, diversifying the food animal portfolio while complementing our companion animal business, including the launch of our new Comfortis chewable flea tablet for dogs. Janssen’s presence, pipeline and people will allow Elanco customers access to broader products and services. Terms of the deal were not disclosed.
“The addition of a strong animal health team along with a number of highly respected brands will further strengthen Elanco’s mission of delivering greater value for our customers,” said Jeff Simmons, president of Elanco. “Elanco continues to invest in and reinforce its commitment to animal health, creating a unique growth opportunities at a time when many are consolidating.”
Products in the acquisition include, among others, Surolan® for treatment of ear infections in dogs and cats, Flubenol® for nematodes in swine and poultry, and Vecoxan® for coccidial infections in calves and lambs.
Elanco will continue to deliver these highly respected brands in the manner customers have come to expect. The products will be continued to be manufactured with the same high standards and quality practices, and the product ordering process will continue as is.